Dataset Information


Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation.

ABSTRACT: Lantibiotics are ribosomally synthesized and post-translationally modified peptide natural products that contain the thioether structures lanthionine and methyllanthionine and exert potent antimicrobial activity against Gram-positive bacteria. At present, detailed modes-of-action are only known for a small subset of family members. Lacticin 481, a tricyclic lantibiotic, contains a lipid II binding motif present in related compounds such as mersacidin and nukacin ISK-1. Here, we show that lacticin 481 inhibits PBP1b-catalyzed peptidoglycan formation. Furthermore, we show that changes in potency of analogues of lacticin 481 containing non-proteinogenic amino acids correlate positively with the potency of inhibition of the transglycosylase activity of PBP1b. Thus, lipid II is the likely target of lacticin 481, and use of non-proteinogenic amino acids resulted in stronger inhibition of the target. Additionally, we demonstrate that lacticin 481 does not form pores in the membranes of susceptible bacteria, a common mode-of-action of other lantibiotics.

PROVIDER: S-EPMC3501146 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2008-01-01 | S-EPMC2574844 | BioStudies
2000-01-01 | S-EPMC94678 | BioStudies
2013-01-01 | S-EPMC3736828 | BioStudies
| S-EPMC2737179 | BioStudies
1000-01-01 | S-EPMC2709986 | BioStudies
2000-01-01 | S-EPMC111008 | BioStudies
| S-EPMC2532561 | BioStudies
1000-01-01 | S-EPMC168744 | BioStudies
2007-01-01 | S-EPMC2517117 | BioStudies
2007-01-01 | S-EPMC2517114 | BioStudies